FindTrial
Sign In

Remission induction with rituximab in Japanese patients with ANCA-associated vascutlitis

Remission induction with rituximab in Japanese patients with ANCA-associated vascutlitis - RemIRIT

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000020329
Enrollment
50
Registered
2016-01-25
Start date
2016-01-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA-associated vasculitis

Interventions

None listed

Sponsors

The strategic study group to establish evidences for the treatment guidelines of intractable vasculitis
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: MPA and GPA patient treated with rituximab

Exclusion criteria

Exclusion criteria: patient lower than 20 years-old

Design outcomes

Primary

MeasureTime frame
remission rate—

Countries

Japan

Contacts

Public ContactKenji Nagasaka

Tokyo Medical and Dental University Dept. of Pharmacovigilance

nagasaka.phv@tmd.ac.jp03-5803-4677

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026